BBMgate is going to be formed in China based on our research achievements in the structure/function of human the sodium-glucose cotransporters. Its core technology is engineering chemical compounds, peptides that specifically target the sodium-glucose cotransporters. This allows us to develop new glucose-lowering drugs for the treatment of diabetes through blocking the function of the cotransporter, and to improve  the oral bioavailablity of existing drugs by engineering molecules that can be transported by the sodium-glucose cotransporters.  BBMgate intend to build a staff base and to fund operating expenditure for three years. At this point the company should have a neutral cash flow from its research services revenues, and a greatly expanded its ability to market the glucose-lowering drugs in China. As a biotech investment opportunity, BBMgate is unusual in that it couples relatively low start-up and ongoing costs, an early revenue stream, and significant scope for growth in asset value.